WO2003020201A3 - Pre-melanges de polypeptide glp-1 et d'insuline basale - Google Patents

Pre-melanges de polypeptide glp-1 et d'insuline basale Download PDF

Info

Publication number
WO2003020201A3
WO2003020201A3 PCT/US2002/021856 US0221856W WO03020201A3 WO 2003020201 A3 WO2003020201 A3 WO 2003020201A3 US 0221856 W US0221856 W US 0221856W WO 03020201 A3 WO03020201 A3 WO 03020201A3
Authority
WO
WIPO (PCT)
Prior art keywords
glp
mixes
basal insulin
basal
insulin
Prior art date
Application number
PCT/US2002/021856
Other languages
English (en)
Other versions
WO2003020201A2 (fr
Inventor
Michael Rosario Defelippis
Richard Dennis Dimarchi
Kingman Ng
Original Assignee
Lilly Co Eli
Michael Rosario Defelippis
Richard Dennis Dimarchi
Kingman Ng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Michael Rosario Defelippis, Richard Dennis Dimarchi, Kingman Ng filed Critical Lilly Co Eli
Priority to EP02753368A priority Critical patent/EP1432430A4/fr
Priority to CA002452044A priority patent/CA2452044A1/fr
Priority to MXPA04001560A priority patent/MXPA04001560A/es
Priority to US10/486,333 priority patent/US7238663B2/en
Priority to JP2003524515A priority patent/JP2005508895A/ja
Publication of WO2003020201A2 publication Critical patent/WO2003020201A2/fr
Publication of WO2003020201A3 publication Critical patent/WO2003020201A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des préparations de pré-mélanges comprenant un polypeptide GLP-1 et une insuline basale.
PCT/US2002/021856 2001-08-28 2002-08-23 Pre-melanges de polypeptide glp-1 et d'insuline basale WO2003020201A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02753368A EP1432430A4 (fr) 2001-08-28 2002-08-23 Pre-melanges de polypeptide glp-1 et d'insuline basale
CA002452044A CA2452044A1 (fr) 2001-08-28 2002-08-23 Pre-melanges de polypeptide glp-1 et d'insuline basale
MXPA04001560A MXPA04001560A (es) 2001-08-28 2002-08-23 Premezclas de glp-1 e insulina basal.
US10/486,333 US7238663B2 (en) 2001-08-28 2002-08-23 Pre-mixes of GLP-1 and basal insulin
JP2003524515A JP2005508895A (ja) 2001-08-28 2002-08-23 Ｇｌｐ−１および基礎インスリンの予備混合物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31546001P 2001-08-28 2001-08-28
US60/315,460 2001-08-28
US38526602P 2002-05-31 2002-05-31
US60/385,266 2002-05-31
US38606102P 2002-06-04 2002-06-04
US60/386,061 2002-06-04

Publications (2)

Publication Number Publication Date
WO2003020201A2 WO2003020201A2 (fr) 2003-03-13
WO2003020201A3 true WO2003020201A3 (fr) 2003-07-03

Family

ID=27405797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021856 WO2003020201A2 (fr) 2001-08-28 2002-08-23 Pre-melanges de polypeptide glp-1 et d'insuline basale

Country Status (7)

Country Link
US (1) US7238663B2 (fr)
EP (1) EP1432430A4 (fr)
JP (1) JP2005508895A (fr)
CN (1) CN1635900A (fr)
CA (1) CA2452044A1 (fr)
MX (1) MXPA04001560A (fr)
WO (1) WO2003020201A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846618B2 (en) 2001-06-28 2014-09-30 Novo Nordisk A/S Stable formulation of modified GLP-1
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000654A2 (fr) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification et stabilisation de produits pharmaceutiques a base de peptides et de proteines
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
BR0306706A (pt) * 2002-01-08 2007-03-27 Lilly Co Eli peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica
EP1894591B1 (fr) 2002-03-20 2013-06-26 MannKind Corporation Cartouche pour un appareil d'inhalation
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
CA2518336A1 (fr) * 2003-03-19 2004-11-04 Eli Lilly And Company Composes glp-1 a liaison polyethylene glycol
WO2004105790A1 (fr) * 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions peptidiques pharmaceutiques stabilisees
CN102940879B (zh) 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
CA2527743A1 (fr) * 2003-06-03 2004-12-09 Novo Nordisk A/S Compositions pharmaceutiques peptidiques stabilisees
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
ATE525083T1 (de) * 2003-11-13 2011-10-15 Novo Nordisk As Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
KR101243648B1 (ko) * 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
PL1789434T3 (pl) * 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
EP1791554A2 (fr) * 2004-09-17 2007-06-06 Novo Nordisk A/S Compositions pharmaceutiques contenant de l'insuline et un peptide insulinotropique
EP1814581B1 (fr) * 2004-11-12 2016-03-16 Novo Nordisk A/S Preparations stables de peptides comprenant un analogue du glp-1 acyle et une insuline basale
JP5175103B2 (ja) * 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
US8318668B2 (en) 2005-09-08 2012-11-27 Trustees Of Tufts College Stabilized GLP-1 analogs
HUE028623T2 (en) 2005-09-14 2016-12-28 Mannkind Corp Active substance formulation method based on increasing the affinity of the active ingredient for binding to the surface of crystalline microparticles
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
US8293869B2 (en) * 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
IN2015DN00888A (fr) 2006-02-22 2015-07-10 Mannkind Corp
WO2007113205A1 (fr) * 2006-04-03 2007-10-11 Novo Nordisk A/S Agonistes du peptide glp-1
BRPI0710651A2 (pt) * 2006-04-13 2011-08-23 Sod Conseils Rech Applic composições farmacêuticas de hglp-1, expedina-4 e seus análogos e uso das mesmas
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
ES2628063T3 (es) * 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
CA2677932A1 (fr) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Co-agonistes des recepteurs du glucagon/glp-1
EP1975176A1 (fr) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Nouveaux peptides à fusion GLP-1, leur production et utilisation
BRPI0818874A2 (pt) * 2007-10-24 2015-05-05 Mannkind Corp Liberação de agentes ativos
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
WO2009055740A2 (fr) * 2007-10-24 2009-04-30 Mannkind Corporation Procédé de prévention des effets indésirables produits par glp-1
JP5771005B2 (ja) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
PL2209800T3 (pl) 2007-11-16 2013-12-31 Novo Nordisk As Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
EP2229407B1 (fr) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
ES2570400T3 (es) 2008-06-13 2016-05-18 Mannkind Corp Un inhalador de polvo seco y un sistema para el suministro de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2727161A1 (fr) * 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Analogues de glucagon presentant des tampons de ph physiologique presentant une solubilite et une stabilite ameliorees
CL2009001424A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
CL2009001425A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
WO2009158704A2 (fr) 2008-06-27 2009-12-30 Duke University Agents thérapeutiques comprenant des peptides de type élastine
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
HUE037449T2 (hu) * 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
MX2011006527A (es) * 2008-12-19 2011-08-17 Univ Indiana Res & Tech Corp Agentes medicinales unidos a dipeptido.
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010096052A1 (fr) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
EP2405963B1 (fr) 2009-03-11 2013-11-06 MannKind Corporation Appareil, système et procédé de mesure de résistance d'un inhalateur
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
IN2012DN00377A (fr) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
PT2612677E (pt) * 2009-06-26 2015-09-10 Novo Nordisk As Preparação compreendendo insulina, nicotinamida e arginina
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
WO2011058082A1 (fr) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Composition pharmaceutique comprenant un agoniste de glp-1 et de la méthionine
AR080669A1 (es) * 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
MX2012013005A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g.
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011156476A2 (fr) * 2010-06-08 2011-12-15 Biodel Inc. Insuline présentant un profil de libération basal
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
CA2796894A1 (fr) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Promedicaments peptidiques a base d'amides de la superfamille du glucagon
EP2585102B1 (fr) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Promédicaments insuliniques à base d'amide
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
WO2012054822A1 (fr) 2010-10-22 2012-04-26 Nektar Therapeutics Conjugués polymère-glp 1 pharmacologiquement actifs
WO2012054861A1 (fr) 2010-10-22 2012-04-26 Nektar Therapeutics Conjugués glp-1-polymère ayant une liaison pouvant être rompue
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
AU2012267605C1 (en) * 2011-06-10 2015-09-24 Aquestive Therapeutics, Inc. Combination peptide-nanoparticles and delivery systems incorporating same
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
CA2847246A1 (fr) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Peptides de la superfamille du glucagon presentant une action sur les recepteurs aux glucocorticoides
KR20150023013A (ko) 2012-06-21 2015-03-04 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 수용체 활성을 나타내는 글루카곤 유사체
WO2014012069A2 (fr) 2012-07-12 2014-01-16 Mannkind Corporation Systèmes et procédés de libération de médicament en poudre sèche
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2911690A1 (fr) 2012-10-26 2015-09-02 MannKind Corporation Compositions et procédés de vaccin antigrippal inhalable
CN104902920A (zh) 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
RU2678134C2 (ru) 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MY181626A (en) 2013-04-03 2020-12-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015086730A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 non acylés
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
WO2015086729A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs glp-1/gip
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3206710B1 (fr) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Conjugués d'insuline-incrétines
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
PL3229828T3 (pl) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PT3297654T (pt) 2015-05-22 2021-09-06 Univ Leland Stanford Junior Tratamento de hipoglicemia pós-bariátrica com exendina(9-39)
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
WO2018055539A1 (fr) 2016-09-22 2018-03-29 Wockhardt Limited Composition pharmaceutique contenant de l'insuline glargine tamponnée et un analogue de glp-1
EP3517544A4 (fr) 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. Analogue d'insuline ayant une force de liaison réduite au récepteur d'insuline et son utilisation
CN110267648A (zh) 2016-11-21 2019-09-20 艾格尔峰生物制药有限公司 毒蜥外泌肽(9-39)的缓冲制剂
EP3604328A4 (fr) 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. Complexe d'analogue à l'insuline à affinité réduite pour le récepteur de l'insuline et son utilisation
AR112480A1 (es) 2017-08-24 2019-10-30 Novo Nordisk As Composiciones de glp-1 y sus usos
WO2019066603A1 (fr) * 2017-09-29 2019-04-04 한미약품 주식회사 Conjugué de protéine persistant à efficacité améliorée
WO2021142733A1 (fr) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Thérapie combinatoire comprenant du glp-1 et/ou des analogues de glp-1, et de l'insuline et/ou des analogues de l'insuline
JP2023518645A (ja) * 2020-01-16 2023-05-08 上海仁会生物制▲やく▼股▲ふん▼有限公司 Ｇｌｐ－１の投薬レジメン
AU2021208601A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Glp-1 compositions and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277877B1 (en) * 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
HU217684B (hu) 1993-09-17 2000-03-28 Novo Nordisk A/S Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DK0821006T3 (da) * 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
CA2306905A1 (fr) * 1997-10-24 1999-05-06 Eli Lilly And Company Analogues d'insuline acylee par un acide gras
DK1032587T4 (da) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonist-forbindelser
ATE381939T1 (de) 1997-11-14 2008-01-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1056775B1 (fr) * 1998-02-27 2010-04-28 Novo Nordisk A/S Derives de gpl-1 et de l'extendine au profil d'action etendu
EP1056774A1 (fr) * 1998-02-27 2000-12-06 Novo Nordisk A/S Derives de glp-1 tronques a l'extremite n-terminale
JP2002512175A (ja) * 1998-02-27 2002-04-23 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１類似体の誘導体類
EP1062240B1 (fr) * 1998-02-27 2010-04-28 Novo Nordisk A/S Derives de glp-1 modifies a l'extremite n-terminale
EP1306091A3 (fr) * 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation de la prolifération des cellules de beta
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
CA2358107C (fr) 1998-12-22 2011-08-23 Eli Lilly And Company Formulation de longue conservation de peptide-1 de type glucagon
EP1175443A1 (fr) 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Exendines modifiees et agonistes de l'exendine
EP1196189A2 (fr) * 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Therapie anti diabete a agents multiples
AU2002346490A1 (en) 2001-12-20 2003-07-09 Eli Lilly And Company Insulin molecule having protracted time action

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277877B1 (en) * 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VELLA ET AL.: "Effect of glucagon-like peptide 1 (7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes", DIABETES, vol. 49, April 2000 (2000-04-01), pages 611 - 617, XP002960983 *
ZANDER ET AL.: "Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes", vol. 24, no. 4, April 2001 (2001-04-01), pages 720 - 725, XP002960984 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846618B2 (en) 2001-06-28 2014-09-30 Novo Nordisk A/S Stable formulation of modified GLP-1
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease

Also Published As

Publication number Publication date
EP1432430A4 (fr) 2006-05-10
CN1635900A (zh) 2005-07-06
JP2005508895A (ja) 2005-04-07
MXPA04001560A (es) 2004-05-17
US7238663B2 (en) 2007-07-03
CA2452044A1 (fr) 2003-03-13
WO2003020201A2 (fr) 2003-03-13
EP1432430A2 (fr) 2004-06-30
US20040235710A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
WO2003020201A3 (fr) Pre-melanges de polypeptide glp-1 et d'insuline basale
AU2002248464A1 (en) Stabilized insulin formulations
AU2002364517A1 (en) Tramadol analogs and uses thereof
AU2002352344A1 (en) Medicament delivery assembly
AU2002302409A1 (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
AU2002364893A1 (en) Delivery of medicaments to the nail
AU2003265595A1 (en) Processes for the preparation of 2-chloro-1,1,1,2,3,3,3-heptafluoropropane, hexafluoropropene and 1,1,1,2,3,3,3-heptafluoropropane
WO2003035686A3 (fr) Gonadotrophines pour la folliculogenese
AU2002335148A1 (en) Single use safety syringe
MXPA03005980A (es) Composiciones para administracion nasal de insulina.
AU2002240942A1 (en) Improved delivery of benefit agents
AU2002221167A1 (en) Safety syringe
AU2002247861A1 (en) Modified calcitonin
AU2002330245A1 (en) Isolated polypeptides and compositions from the venom of p. transvaalicus and methods of use
AU2002250977A1 (en) Combination of active ingredients consisting of the racemate of tramadol and of (+)-o-desmethyltramadol
AU2002349142A1 (en) Syringe
HUP0401229A3 (en) Crystal form of a phenylethanolamine hydrokloride, the preparation thereof and pharmaceutical compositions comprising the same
AU2002333290A1 (en) Regulator of calcineurin
AU2002345397A1 (en) Safety syringe
AU2001277750A1 (en) Use of polypeptide
USD469993S1 (en) Leg for a work station
AU2002304733A1 (en) Amino-aza-cyclohexanes for the treatment of malaria
AU2002241396A1 (en) Short turnaround time insulin or c-peptide assay
AU2002321543A1 (en) Anaesthetic formulations of propofol
AU2002311203A1 (en) Novel polypeptide and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NO NZ OM PH PT RO RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2452044

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002313662

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10486333

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001560

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 254/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003524515

Country of ref document: JP

Ref document number: 20028171179

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002753368

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002753368

Country of ref document: EP

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0211539

Country of ref document: BR

Free format text: PEDIDO RETIRADO FACE A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL POR TER SIDO INTEMPESTIVA. O PRAZO PARA ENTRADA NA FASE NACIONAL EXPIRAVA EM 28.04.2003 ( 20 MESES - BR DESIGNADO APENAS), ELEICAO NAO COMPROVADA, E A PRETENSA ENTRADA NA FASE NACIONAL SO OCORREU EM 28.01.2004.

WWW Wipo information: withdrawn in national office

Ref document number: 2002753368

Country of ref document: EP